Dermapharm Holding SE | WebDisclosure

Switch to English

10896	Sociétés
237341	Mots-clés
166228	Articles
127412	Communiqués

Accueil
Sociétés
Dermapharm Holding SE

COMMUNIQUÉ DE PRESSE

publié le 10/03/2026 à 09:11, il y a 5 mois 18 jours

EQS-Adhoc: Dermapharm Holding SE resolves public share buyback offer for up to 4,300,000 shares
Dermapharm Holding SE resolves public share buyback offer for up to 4,300,000 shares, at EUR 42.00 per share. Details at https://ir.dermapharm.de

Investor Relations Share Buyback Offer Public Offer Dermapharm Holding SE EUR 42.00 Per Share
BRÈVE

publiée le 10/03/2026 à 07:35, il y a 5 mois 18 jours

Dermapharm annonce une baisse de son chiffre d'affaires, mais une amélioration de son EBITDA en 2025

Baisse Des Revenus Produits De Santé Croissance De L'EBITDA Dermapharm Résultats De 2025
BRÈVE

publiée le 10/03/2026 à 07:35, il y a 5 mois 18 jours

Dermapharm Reports Revenue Decline, EBITDA Improvement in 2025

Revenue Decline EBITDA Growth Healthcare Products Dermapharm 2025 Earnings
COMMUNIQUÉ DE PRESSE

publié le 10/03/2026 à 07:30, il y a 5 mois 18 jours

Dermapharm Holding SE records decline in consolidated revenue, adjusted consolidated EBITDA improves
Dermapharm Holding SE reports decline in consolidated revenue for 2025 but shows improved adjusted consolidated EBITDA margins. Company's earnings and margins heavily impacted by structural measures

Adjusted EBITDA Pharmaceuticals Consolidated Revenue Annual Results Dermapharm Holding SE
BRÈVE

publiée le 13/11/2025 à 07:35, il y a 9 mois 15 jours

Dermapharm maintient sa stabilité malgré les ajustements de son portefeuille

Croissance Et Bénéfices Dermapharm Restructuration Du Portefeuille Résultats Financiers De 2025 Médicaments De Marque
BRÈVE

publiée le 13/11/2025 à 07:35, il y a 9 mois 15 jours

Dermapharm Maintains Stability Amid Portfolio Adjustments

Growth And Earnings Branded Pharmaceuticals Dermapharm 2025 Financial Results Portfolio Restructuring
COMMUNIQUÉ DE PRESSE

publié le 13/11/2025 à 07:30, il y a 9 mois 15 jours

Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong growth in branded pharmaceuticals
Dermapharm Holding SE reports stable earnings despite portfolio adjustments in Q3 2025, confirms 2025 guidance and strong growth in branded pharmaceuticals

Pharmaceuticals Growth Earnings Dermapharm Holding SE Portfolio Adjustment
BRÈVE

publiée le 26/08/2025 à 07:35, il y a 1 année

Dermapharm Reports Stable Business in H1 2025 and Q2 EBITDA Growth

Financial Results EBITDA Growth Revenue Stability Branded Pharmaceuticals Dermapharm Performance
BRÈVE

publiée le 26/08/2025 à 07:35, il y a 1 année

Dermapharm annonce une activité stable au premier semestre 2025 et une croissance de l'EBITDA au deuxième trimestre

Résultats Financiers Croissance De L'EBITDA Stabilité Des Revenus Produits Pharmaceutiques De Marque Performances De Dermapharm
COMMUNIQUÉ DE PRESSE

publié le 26/08/2025 à 07:30, il y a 1 année

Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter
Dermapharm confirms stable business development in H1 2025 with EBITDA growth in Q2. Full-year guidance for 2025 reiterated. Branded pharmaceuticals main growth driver

Revenue Pharmaceuticals EBITDA Growth Dermapharm H1 2025

Les Echos

Publié le 28/08/2026 à 06:55, il y a 6 heures 16 minutes

Recticel Accelerates Profitable Growth
Publié le 28/08/2026 à 06:55, il y a 6 heures 16 minutes

Recticel versnelt winstgevende groei
Publié le 26/08/2026 à 18:02, il y a 1 jour 19 heures

Altareit: Altarea press release regarding the Primonial matter
Publié le 26/08/2026 à 18:02, il y a 1 jour 19 heures

Altareit : Communiqué de presse d’Altarea relatif au dossier Primonial
Publié le 26/08/2026 à 18:00, il y a 1 jour 19 heures

Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 28/08/2026 à 13:00, il y a 11 minutes

Abasca Files NI 43-101 Technical Report, Commences Summer Exploration Program at Loki and Elects to File Semi-annual Interim Financial Statements and Related MD&A
Publié le 28/08/2026 à 08:05, il y a 5 heures 6 minutes

Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
Publié le 28/08/2026 à 08:05, il y a 5 heures 6 minutes

Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
Publié le 28/08/2026 à 08:00, il y a 5 heures 11 minutes

Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate
Publié le 28/08/2026 à 04:30, il y a 8 heures 41 minutes

Snipp Interactive Reports Q2 2026 Financial Results; Returns to Positive EBITDA on Highest Quarterly Revenue in Five Quarters

Voir tout ACCESSWIRE

EQS Group

Publié le 28/08/2026 à 13:00, il y a 11 minutes

Half-year Financial Report
Publié le 28/08/2026 à 12:43, il y a 28 minutes

Annual General Meeting of MPC Capital AG approves change of name to MPC Oceanic Group AG
Publié le 28/08/2026 à 12:43, il y a 28 minutes

IVU and Hellenic Train collaborate to enhance Rail Mobility in Greece
Publié le 28/08/2026 à 11:30, il y a 1 heure 41 minutes

Halfords Group PLC: Holding in Company
Publié le 28/08/2026 à 11:15, il y a 1 heure 56 minutes

Redcare Pharmacy announces Managing Board succession: Peter Schmid von Linstow to succeed Olaf Heinrich as part of a planned leadership transition.